This landmark investment reflects not only America's importance but also our confidence in our innovative medicines to transform global health and power AstraZeneca's ambition to deliver $80 billion ...

AstraZeneca has announced a jump in sales in recent months after a surge in demand for cancer drugs, as the pharmaceutical ...

Total revenue rose 11 per cent to $28bn (£12.98bn) in the first half of the year, driven by double-digit growth in Oncology ...

Cambridge headquartered AstraZeneca saw its UK share price rocket 328p to 11,118 and its market cap soar to £173.49 billion after a stunning set of results for the first half and second quarter of ...

Barclays today said half-year pre-tax profits rose 23% to £5.2 billion, boosted by a 28% improvement in the second quarter of ...

Revenue from oncology products made up 43 per cent of Astrazeneca's revenue in the first half of 2025, up 15 per cent year on ...

The AstraZeneca share price has been treading water for the past few years, but first-half results add strength to rising ...

Drugmaker Astrazeneca said on Tuesday that "strong growth momentum" had continued in H1, with "excellent R&D pipeline ...

Pharmaceutical giant AstraZeneca has reported increased revenue across all its major geographic regions and increased interim profits as the listed business maintained its growth ...

The Anglo-Swedish pharmaceutical giant said Tuesday that for the second quarter, core earnings per share rose to $2.17 from $1.98 in the same period a year prior. Revenue increased to $14.46 billion ...

AstraZeneca PLC (NASDAQ: AZN) ranks among the stocks to benefit from an onshoring boom. AstraZeneca PLC (NASDAQ:AZN) ...